Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-09-05-Speech-2-325"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-09-05"^^xsd:date2
dcterms:Is Part Of	lp_eu:Counterfeiting of medicines (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20060905.26.2-325"2
lpv:hasSubsequent	lp_eu:2006-09-05-Speech-2-3262
lpv:speaker	lp:Marie-Hélène Aubert2
lpv:spokenAs	member; AGRI (2004-07-21--2007-01-14)3 member; PECH (2004-07-21--2007-01-14)3 unknown; Les Verts-Europe-Ecologie (2004-07-20--2009-07-13)3 substitute; DEVE (2004-07-21--2007-01-14)3 member; G/EFA (2004-07-20--2007-02-26)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2004-09-15--2007-06-23)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2004-09-15--2009-07-13)3
lpv:translated text	". Commissioner, the counterfeiting of medicines is, indeed, a particularly serious scourge and one that, unfortunately, is not new and that has even been known about for several years. It might therefore be hoped that our fellow Member’s timely question will finally lead to some results. That being said, the main motive for counterfeiting medicines has to do with the fact that they are much too highly priced for poor countries and their populations. The first tactic should therefore consist in ensuring that poor countries and the most impoverished populations have access to generic medicines. This is something that my fellow Member has spoken about. Generic medicines still do not have a significant enough place on the medicines market. Furthermore, I would not want the fight against counterfeiting to consist in reinforcing the protection of patents in the pharmaceutical sphere and so protecting the future development of the already considerable profits made by the pharmaceutical industry in many sectors. The priority is, therefore, to encourage the development of public health policies in the countries concerned, as well as to encourage the establishment of states governed by the rule of law. That is indeed the priority. Nothing is possible unless viable states and public health policies are established enabling, in particular, medicines to be monitored and pharmacies to be set up in accordance with properly laid down rules. This issue of a public health policy is one basic element, the other being prevention. Indeed, health is not just about medicines. In other words, swallowing medicines is not the only route to good health. For example, unclean drinking water is at present a cause of death in a number of developing countries. Another example relates to AIDS. The counterfeiting of medicines is highly developed in this area, and the recently held Onusida conference placed great emphasis on prevention. It is therefore also through policies of prevention, information and education and by relying on the practical knowledge present in local communities that attempts might be made to solve the problem and not merely through putting dozens of substances on the market at prohibitive prices. In conclusion, I think that, in the fight against counterfeiting, we have to begin by strengthening existing measures and coordinating them better. Then, we must above all help the developing, or poorest, countries to establish viable states and to put public policies in place covering all health problems and not only that of access to medicines."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph